Fig. 4: Azacitidine pre-treatment enhances anti-CD123 CAR T cell-mediated AML elimination.

a Representative gating strategy used for flow cytometry-based analysis of total human CD45 cells, residual MOLM-13 CD123⁺ leukemia cells as well as residual CD4⁺/CD8⁺ T cells in the BM of mice treated with PBS, NTD Tc, anti-CD123 CAR Tc, AZA only, NTD Tc + AZA or anti-CD123 CAR Tc + AZA. Flow cytometric analysis depicting absolute cell counts (cells/μL) of residual b hCD45⁺ and c CD123⁺ MOLM-13 leukemia cells in the BM of the various treatment groups (PBS n = 8; NTD Tc n = 8; AZA n = 8; NTD Tc + AZA n = 8; anti-CD123 CAR Tc n = 8; anti-CD123 CAR Tc + AZA n = 8). All graphed data were pooled from two independent experiments and are represented as mean ± SEM. p-values were calculated using two-sided one-way ANOVA (Kruskal–Wallis test with Dunn’s multiple comparisons).